Patents by Inventor Blaine Christiansen

Blaine Christiansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION
    Publication number: 20230109457
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: May 9, 2022
    Publication date: April 6, 2023
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • Use of CDK9 inhibitors to reduce cartilage degradation
    Patent number: 11351161
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: June 7, 2022
    Assignee: The Regents Of The University Of California
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION
    Publication number: 20210008054
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: April 30, 2020
    Publication date: January 14, 2021
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dominik HAUDENSCHILD, Paul DI CESARE, Jasper YIK, Blaine CHRISTIANSEN
  • Use of CDK9 inhibitors to reduce cartilage degradation
    Patent number: 10639302
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 5, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION
    Publication number: 20190255034
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: November 20, 2018
    Publication date: August 22, 2019
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dominik HAUDENSCHILD, Paul Di CESARE, Jasper YIK, Blaine CHRISTIANSEN
  • Use of CDK9 inhibitors to reduce cartilage degradation
    Patent number: 10172844
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 8, 2019
    Assignee: The Regents of the University of California
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION
    Publication number: 20170246156
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: November 18, 2016
    Publication date: August 31, 2017
    Applicant: The Regents of the University of California
    Inventors: Dominik HAUDENSCHILD, Paul Di CESARE, Jasper YIK, Blaine CHRISTIANSEN
  • Use of CDK9 inhibitors to reduce cartilage degradation
    Patent number: 9498471
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: November 22, 2016
    Assignee: The Regents of the University of California
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION
    Publication number: 20150105423
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: October 19, 2012
    Publication date: April 16, 2015
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • Bipolar sieve electrode and method of assembly
    Patent number: 8792973
    Abstract: Apparatus for providing an interface between a nerve and an external information system. The apparatus includes a substrate having a first surface, an opposite second surface, and an electrode body, wherein the electrode body includes a plurality of holes extending therethrough. The apparatus also includes a plurality of electrical leads embedded within the substrate and a plurality of ring electrodes, wherein each of the ring electrodes circumscribes a corresponding hole, and wherein at least a portion of the ring electrodes is positioned on each of the first surface and the second surface.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: July 29, 2014
    Assignee: Washington University
    Inventors: Daniel Moran, Blaine Christiansen, Matthew MacEwan
  • Bipolar Sieve Electrode And Method Of Assembly
    Publication number: 20110251473
    Abstract: Apparatus for providing an interface between a nerve and an external information system. The apparatus includes a substrate having a first surface, an opposite second surface, and an electrode body, wherein the electrode body includes a plurality of holes extending therethrough. The apparatus also includes a plurality of electrical leads embedded within the substrate and a plurality of ring electrodes, wherein each of the ring electrodes circumscribes a corresponding hole, and wherein at least a portion of the ring electrodes is positioned on each of the first surface and the second surface.
    Type: Application
    Filed: November 23, 2009
    Publication date: October 13, 2011
    Applicant: Washington University in St. Louis
    Inventors: Daniel Moran, Blaine Christiansen, Matthew MacEwan